Eric Hedrick
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 18
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment 18
- Oncology top 1%
- Colorectal Cancer Treatments and Studies 12
- Cancer Treatment and Pharmacology 7
- Viral-associated cancers and disorders 6
- Hepatology top 2%
- Hematology top 2%
- Chronic Myeloid Leukemia Treatments 6
-
- Gastric Cancer Management and Outcomes 6
-
- Cancer Genomics and Diagnostics 5
- Co-authors
- Axel GrotheyDaniel J. SargentMary M. SugrueMark KozloffWei DongDavid M. PurdieRamesh K. RamanathanBarrett H. Childs
- Partner nations
- United StatesAustraliaChina
In The Last Decade
Eric Hedrick
39 papers receiving 4.0k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Genetics 1.4k
- Pathology and Forensic Medicine 2.0k
- Oncology 2.2k
- Hepatology 438
- Hematology 461
Countries citing papers authored by Eric Hedrick
This map shows the geographic impact of Eric Hedrick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric Hedrick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric Hedrick more than expected).
Fields of papers citing papers by Eric Hedrick
This network shows the impact of papers produced by Eric Hedrick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric Hedrick. The network helps show where Eric Hedrick may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Eric Hedrick, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2020 | 2 | |
| 2 | Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 studybreakdown → | 2018 | 451 |
| 3 | 2017 | 1 | |
| 4 | 2017 | 15 | |
| 5 | 2017 | 5 | |
| 6 | 2016 | 11 | |
| 7 | 2015 | 2 | |
| 8 | Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignanciesbreakdown → | 2012 | 848 |
| 9 | 2012 | 29 | |
| 10 | 2012 | 23 | |
| 11 | 2011 | 45 | |
| 12 | 2011 | 34 | |
| 13 | Bevacizumab Beyond First Progression Is Associated With Prolonged Overall Survival in Metastatic Colorectal Cancer: Results From a Large Observational Cohort Study (BRiTE)breakdown → | 2008 | 519 |
| 14 | 2007 | 1 | |
| 15 | 2006 | 19 | |
| 16 | 2004 | 25 | |
| 17 | 2003 | 109 | |
| 18 | 2002 | 140 | |
| 19 | 2001 | 52 | |
| 20 | 2001 | 310 |
About Eric Hedrick
Eric Hedrick is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 39 papers that have together received 4.1k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (18 papers), Lymphoma Diagnosis and Treatment (18 papers), Colorectal Cancer Treatments and Studies (12 papers), Cancer Treatment and Pharmacology (7 papers), Chronic Myeloid Leukemia Treatments (6 papers), Viral-associated cancers and disorders (6 papers), Gastric Cancer Management and Outcomes (6 papers) and Cancer Genomics and Diagnostics (5 papers). The work is most often cited by research in Genetics (1.4k citations), Pathology and Forensic Medicine (2.0k citations) and Oncology (2.2k citations). Eric Hedrick has collaborated with scholars based in United States, Australia and China. Frequent co-authors include Axel Grothey, Daniel J. Sargent, Mary M. Sugrue, Mark Kozloff, Wei Dong, David M. Purdie, Ramesh K. Ramanathan, Barrett H. Childs, John D. Hainsworth and Jeff P. Sharman. Their work appears in journals such as Journal of Clinical Oncology, Blood, Hematological Oncology, Cancer and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.